Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US38341P1021
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00MVWLLM2
GOSS
Gossamer Bio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Gossamer Bio Inc
ISIN
US38341P1021
TICKER
GOSS
MIC
XNAS
REUTERS
GOSS.OQ
BLOOMBERG
GOSS US
Do., 02.04.2026       Gossamer Bio
US38341P1021

The Law Offices of Frank R. Cruz announces an investigation of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSSAMER BIO, INC. (GOSS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Gossamer Bio
US38341P1021

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Invest...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Gossamer Bio
US38341P1021

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Gossamer Bio
US38341P1021

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, April 1, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Fahee...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Compa...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 25, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Fahe...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio CEO Expressed Optimism About PROSERA Trial Outcome; the Study Missed Its Primary Endpoint Months LaterNEW YORK, March 18, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders suffered significant losses when the Company disclosed that its Phase 3 PROSERA study of seralutinib missed its primary 6-minute walk distance end...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 17.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Compan...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More LikelyNEW YORK, March 4, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Faheem...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Compan...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
So., 01.03.2026       Gossamer Bio
US38341P1021

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       Gossamer Bio
US38341P1021

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced topline results for the PROSERA Phase 3 Study of seralutinib in patie...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 08.01.2026       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 24.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the follow...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the follow...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter end...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Gossamer Bio
US38341P1021

- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif., Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has ent...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acqu...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 22.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralut...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 10.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 29.08.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 16.06.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global r...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 06.06.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 15.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter end...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 fina...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the America...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 08.04.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 13.03.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter an...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 07.03.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 07.02.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 03.02.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seraluti...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.01.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced one oral and three poster presentations related to se...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 11.11.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended Sep...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 07.10.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 26.08.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 12.08.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended Ju...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 03.02.2023       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and c...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink